CompletedNot Applicable

Invasive Fungal Infections in Patients Following Stem Cell Transplant

Australia300 participantsStarted 2022-01-15

Plain-language summary

This study will be a descriptive, retrospective evaluation and analysis of invasive fungal infections (IFI) conducted in patients who underwent allogeneic haematopoiectic stem cell transplant (aHSCT) in a single tertiary transplant centre, the Bone Marrow Transplant Clinical Service across Peter MacCallum Cancer Centre (PMCC) and Royal Melbourne Hospital (RMH), Victoria, Australia.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All patients who are above 18 years of age, * Who underwent allogeneic haematopoietic stem cell transplant (aHSCT) from 1 January 2017 to 1 January 2019 with the Bone Marrow Transplant Clinical Service at Royal Melbourne Hospital (RMH) \& Peter MacCallum Cancer Centre (PMCC), Victoria, Australia * Only the first transplant procedure will be included in the analysis Exclusion Criteria: * None

What they're measuring

Incidence of invasive fungal infections (IFI) in patients

Timeframe: One year

Trial details

NCT IDNCT04619147

SponsorPeter MacCallum Cancer Centre, Australia

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-04-20

View on ClinicalTrials.gov More Invasive Fungal Infections trials